The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 5, 2008, Pages 2163-2171

  Cai, Jun ^a   Kehoe, Oksana ^b   Smith, Gill M ^b   Hykin, Philip ^c   Boulton, Michael E ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; F ACTIN; MICROSOMAL AMINOPEPTIDASE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; LIPOCORTIN 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL LOSS; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; COW; DIABETIC RETINOPATHY; DISEASE COURSE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; RETINA CELL; WESTERN BLOTTING; WOUND HEALING; ANIMAL; CATTLE; CELL CULTURE; CELL MOTION; DRUG EFFECT; METABOLISM; PATHOLOGY; RETINA BLOOD VESSEL; UPREGULATION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; ANNEXIN A5; ANTIGENS, CD13; APOPTOSIS; BLOTTING, WESTERN; CATTLE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; PERICYTES; RECEPTOR, TIE-2; RETINAL VESSELS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 44649189401     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1206     Document Type: Article

References (48)

1. Miller J, D'Amico D. Proliferative diabetic retinopathy. In: Albert D, Jakobiec F, eds. Principles and Practice of Ophthalmology. Philadelphia: WB Saunders; 1994:760-782.
2. Hammes HP, Lin J, Wagner P, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes. 2004;53:1104-1110.
3. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye. 2002;16:242-260.
4. Ishibashi T, Inomata H, Sakamoto T, Ryan SJ. Pericytes of newly formed vessels in experimental subretinal neovascularization. Arch Ophthalmol. 1995;113:227-231.
5. Takagi H, Koyama S, Seike H, et al. Potential role of the angiopoi- etin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:393-402.
6. Jones N, Master Z, Jones J, et al. Identification of Tek/Tie2 binding partners: binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem. 1999;274:30896-30905.
7. Jones N, Voskas D, Master Z, Sarao R, Jones J, Dumont DJ. Rescue of the early vascular defects in Tek/Tie2 null mice reveals an essential survival function. EMBO Rep. 2001;2:438-445.
8. Fadel BM, Boutet SC, Quertermous T. Octamer-dependent in vivo expression of the endothelial cell-specific Tie2 gene. J Biol Chem. 1999;274:20376-20383.
9. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
10. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the Tie2 receptor, by secretion-trap expression cloning. Cell. 1996;87:1161-1169.
11. Puri MC, Bernstein A. Requirement for the TIE family of receptor tyrosine kinases in adult but not fetal hematopoiesis. Proc Natl Acad Sci USA. 2003;100:12753-12758.
12. Park YS, Kim NH, Jo I. Hypoxia and vascular endothelial growth factor acutely up-regulate angiopoietin-1 and Tie2 mRNA in bovine retinal pericytes. Microvasc Res. 2003;65:125-131.
13. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171-1180.
14. Hawighorst T, Skobe M, Streit M, et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am JPathol. 2002;160: 1381-1392.
15. Kampfer H, Pfeilschifter J, Frank S. Expressional regulation of angiopoietin-1 and -2 and the Tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Lab Invest. 2001;81:361-373.
16. Yamakawa M, Liu LX, Belanger AJ, et al. Expression of angiopoi- etins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis. Am JPhysiol. 2004; 287:F649-F657.
17. Hanahan D. Signaling, vascular morphogenesis and maintenance. Science. 1997;277:48-50.
18. Hackett SF, Ozaki H, Strauss RW, et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neo- vascularization. J Cell Physiol. 200;184:275-284.
19. Cai J, Ahmad S, Jiang WG, et al. Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes. 2003;52:2959-2968.
20. Griffin JD, Ritz J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Lab Invest. 1981;68:932-941.
21. Ramsauer M, Krause D, Dermietzel R. Angiogenesis of the blood- brain barrier in vitro and the function of cerebral pericytes. FASEB J. 2002;16:1274-1276.
22. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem. 2006;281:3604-3613.
23. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996;84:359-369.
24. Reusch P, Barleon B, Weindel K, et al. Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. Angiogenesis. 2001;4:123-131.
25. Ikeda N, Nakajima Y, Tokuhara T, et al. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res. 2003;9:1503-1508.
26. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes. 2001;50: 1636-1642.
27. Chakravarthy U, Gardiner TA. Endothelium-derived agents in pericyte function/dysfunction. Prog Retin Eye Res. 1999;18:511-527.
28. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277:242-245.
29. Miller AG, Smith DG, Bhat M, Nagaraj RH. Glyoxalase is critical for human retinal capillary pericyte survival under hyperglycaemic conditions. J Biol Chem. 2006;281:11864-11871.
30. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenz M. Activation of nuclear factor-B induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes. 2002;51: 2241-2248.
31. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res. 2001;49:659-670.
32. Iurlaro M, Scatena M, Zhu WH, et al. Rat aorta-derived mural precursor cells express the Tie2 receptor and respond directly to stimulation by angiopoietins. J Cell Sci. 2003;116:3635-3643.
33. Ohashi H, Takagi H, Koyama S, et al. Alterations in expression of angiopoietins and the Tie-2 receptor in the retina ofstreptozotocin induced diabetic rats. Mol Vis. 2004;10:608-617.
34. Yabkowitz R, Meyer S, Black T, Elliott G, Merewether LA, Yamane HK. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human en- dothelial cells via metalloprotease activation. Blood. 1999;93: 1969-1979.
35. Ozerdem U, Stallcup WB. Early contribution of pericytes to angio- genic sprouting and tube formation. Angiogenesis. 2003;6:241-249.
36. Bogdanovic E, Nguyen VPKH, Dumont DJ. Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization. J Cell Sci. 2006;119:3551-3560.
37. Shimamura M, Hazato T, Iwaguchi T. Enkephalin-degrading ami- nopeptidase in the longitudinal muscle layer of guinea pig small intestine: its properties and action on neuropeptides. JBiochem. 1991;109:492-497.
38. Olsen J, Cowell GM, Konigshofer E, et al. Complete amino acid sequence of human intestinal aminopeptidase N as deduced from cloned cDNA. FEBS Lett. 1988;238:307-314.
39. Ashmun RA, Look AT. Metalloprotease activity ofCD13/aminopep- tidase N on the surface of human myeloid cells. Blood. 1990;75: 462-469.
40. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60:722-727.
41. Chantrain CF, Henriet P, Jodele S, et al. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metallopro- teinases. Eur J Cancer. 2006;42:310-318.
42. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E, Plate KH. Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol. 2004;165:1557-1570.
43. Gamble JR, Drew J, Trezise L, et al. Angiopoietin-1 is an antiper- meability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res. 2000;87:603-607.
44. Kim I, Kim H G, So JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Circ Res. 2000;86:24-29.
45. Gardiner TA, Gibson DS, de Gooyer TE, de la Cruz VF, McDonald DM, Stitt AW. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascular- ization in ischemic retinopathy. Am J Pathol. 2005;166:637-644.
46. Joussen AM, Poulaki V, Mitsiades N. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16:438-440.
47. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235-239.
48. Das A, Fanslow W, Cerretti D, et al. Angiopoietin/Tek interactions regulate MMP-9 expression and retinal neovascularization. Lab Invest. 2003;83:1637-1645.